Novo Nordisk’s Ziltivekimab Fails to Reduce Heart Risks in Major Trial, Casting Doubt on Inflammation Hypothesis.
admin The pharmaceutical landscape shifted dramatically on Friday as Novo Nordisk, the Danish powerhouse currently dominating...
Health
Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
The most significant regulatory news of the week centers on a decisive vote by a...
Up and down the ladder: The latest comings and goings
Bexorg, a company that has largely operated under a veil of scientific intensity since its...
Trump administration revises rebate pilot for 340B drug discount program, angering hospitals
The 340B program, established by Congress in 1992, requires drug manufacturers to provide outpatient drugs...
The Invisible Border: How Funding Bans and Drug Shortages are Fueling a Syphilis Crisis in San Diego’s Shadows
She first came to Park Boulevard for the money and the snacks, a pilgrimage born...
Federal Judge Denies 26 States’ Request to Halt Implementation of Medicaid Work Requirements.
In a pivotal legal decision that carries profound implications for the American social safety net,...
Senate health committee approves nominees for CDC Director and pandemic preparedness leader despite concerns over vaccine skepticism.
In a pivotal session that underscores the shifting landscape of American public health governance, the...
The Readout LOUD: FDA Scrutiny on Duchenne Treatments, Biotech Fugitives, and a C-Suite Shakeup.
The biotechnology sector is currently navigating a period of intense regulatory scrutiny, executive turnover, and...
Ebola outbreak nears milestone, but vaccine is closeÂ
This legal action is not an isolated incident but rather part of a broader regulatory...
FDA Advisory Committee Meeting on Replimune’s RP1 for Melanoma: A Critical Crossroads for Regulatory Policy and Cancer Immunotherapy.
The Food and Drug Administration (FDA) has convened its Cellular, Tissue, and Gene Therapies Advisory...
